Zoetis Inc. (NYSE:ZTS) Shares Acquired by Western Wealth Management LLC

Western Wealth Management LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,325 shares of the company’s stock after purchasing an additional 366 shares during the quarter. Western Wealth Management LLC’s holdings in Zoetis were worth $1,446,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ZTS. Blue Bell Private Wealth Management LLC increased its stake in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares in the last quarter. Evermay Wealth Management LLC increased its stake in shares of Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after acquiring an additional 112 shares during the period. Worth Asset Management LLC acquired a new stake in shares of Zoetis in the first quarter worth $26,000. Finally, Moisand Fitzgerald Tamayo LLC increased its stake in shares of Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after acquiring an additional 96 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS opened at $146.45 on Friday. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The company has a market cap of $66.98 billion, a price-to-earnings ratio of 28.89, a PEG ratio of 2.34 and a beta of 0.85. Zoetis Inc. has a 52-week low of $145.80 and a 52-week high of $201.92. The firm’s fifty day simple moving average is $175.48 and its two-hundred day simple moving average is $180.02.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 earnings per share. Equities analysts anticipate that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.18%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ZTS shares. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group increased their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Barclays increased their price objective on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 14th. Stifel Nicolaus lowered their price target on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Finally, Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $221.75.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 2,209 shares of company stock valued at $371,293 over the last ninety days. Corporate insiders own 0.12% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.